Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

114
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
114
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

131
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
131
Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

80
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
80
The Representativeness Heuristic02:13

The Representativeness Heuristic

15.8K
The representative heuristic describes a biased way of thinking, in which you unintentionally stereotype someone or something. For example, you may assume that your professors spend their free time reading books and engaging in intellectual conversation, because the idea of them spending their time playing volleyball or visiting an amusement park does not fit in with your stereotypes of professors.
15.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

When Emulation Falls Short: Reaffirming the Role of Randomized Clinical Trials.

Circulation. Population health and outcomes·2026
Same author

Perceptions of research participation among underrepresented groups: Insights using freelisting methodology.

PloS one·2026
Same author

Barriers to Optimization of Medical Therapy and the Role of Checklist-Based Decision Support in Heart Failure.

Journal of the American Heart Association·2026
Same author

Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and/or congestion: a landmark analysis of the PARADISE-MI trial.

European journal of heart failure·2026
Same author

Ethical considerations for using alternative methods of consent in neonatal clinical trials: recommendations from a modified Delphi consensus process.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Understanding Motivation to Participate in Clinical Trials: Insights to Diversify Clinical Research Using Health Information National Trends Survey.

Clinical and translational science·2026
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
関連記事をすべて見る

関連する実験動画

Updated: May 29, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

臨床試験における代表性の測定

Allen Sanyi1,2, Samuel Byiringiro3, Sanaz Dabiri4

  • 1Department of Medicine (A.S.), Emory University School of Medicine, Atlanta, GA.

Circulation
|February 3, 2025
PubMed
まとめ
この要約は機械生成です。

臨床試験における代表性の測定は 公平な研究にとって極めて重要です 完璧な方法は1つでもありませんが 多様性,公平性,包摂性,帰属性 (DEIB) を改善する多面的なアプローチは可能です

キーワード:
臨床試験多様性,公平性,包摂性,そして所属性患者募集人種的・民族的少数派

さらに関連する動画

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

関連する実験動画

Last Updated: May 29, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

科学分野:

  • 臨床試験
  • 健康に関する公平性
  • 研究方法論

背景:

  • 臨床試験の代表性は,外部の有効性,研究への公平なアクセス,および公衆の信頼のために不可欠です.
  • 代表性を定量化することは,臨床研究における多様性,公平性,包摂性,帰属性 (DEIB) を達成するための重要なステップです.
  • 臨床試験における特定の集団の伝統的不足は 堅実な測定戦略を必要とします

研究 の 目的:

  • ランダム化臨床試験における代表性を測定するための様々な定量的な方法を探求する.
  • 試験参加者の人口統計を評価するための異なるアプローチの強みと弱みを評価する.
  • 臨床研究におけるDEIBの評価と改善のための適切な指標の選択について,関係者に情報を提供すること.

主な方法:

  • 参加率と罹患率の比率,入学率を含む試験の代表性を測定するための提案された方法のレビュー
  • 利害関係者のニーズと試験の文脈に基づいて,さまざまな定量的な測定の有用性の分析.
  • 定量的代表性目標の使用による意図せざる結果の検討

主要な成果:

  • 代表性を測定する方法は複数あり,それぞれに限界があります.
  • 参加率と罹患率の比率は,明確に定義された人口を対象とした試験に有用です.
  • 入学率と人口統計の組み合わせは 代表性のより微妙な見方を提供します

結論:

  • すべての臨床試験で DEIB を包括的に扱う方法はありません.
  • 代表性を測定するための慎重に設計された多面的なアプローチが推奨されます.
  • 定量的な測定は 慎重に検討すると 臨床試験参加の多様性を高めるための取り組みを導くことができます